Ocugen Inc
NASDAQ:OCGN
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.
Pipeline Progress: Ocugen is nearing Phase 3 enrollment completion for OCU400 and expects to begin rolling BLA submission in the first half of 2026, with commercialization anticipated in 2027.
OCU410ST Advances: The OCU410ST Phase 2/3 trial is ahead of schedule, with enrollment expected to complete in Q1 2026; interim data are due mid-2026, and BLA submission is planned for the first half of 2027.
Financial Runway: The company raised $20 million in Q3 2025, extending its cash runway through Q2 2026, with potential for $30 million more if warrants are exercised.
Strategic Partnerships: Ocugen signed a South Korea licensing agreement for OCU400, securing upfront and milestone payments and a 25% royalty on net sales.
Manufacturing Readiness: Process validation and manufacturing activities for commercial production are progressing on track, with sufficient capacity anticipated for launch.
Clinical Results: Early data for OCU410ST and OCU410 show promising lesion reduction and visual improvement versus current standards, supporting the gene-agnostic strategy.
